Tscan therapeutics reports first quarter 2024 financial results and provides corporate update

First patient dosed in phase 1 clinical trial for the treatment of solid tumors; initial data anticipated in 2024 all treatment-arm patients in the phase 1 heme program remain relapse-free with no detectable disease, with a median follow-up of >10 months closed upsized underwritten public offering with gross proceeds of $167.8 million, extending runway into the fourth quarter of 2026 waltham, mass., may 13, 2024 (globe newswire) -- tscan therapeutics, inc. (nasdaq: tcrx), a clinical-stage biopharmaceutical company focused on the development of t cell receptor (tcr)-engineered t cell (tcr-t) therapies for the treatment of patients with cancer, today reported financial results for the first quarter ended march 31, 2024, and provided a corporate update.
TCRX Ratings Summary
TCRX Quant Ranking